Navigation Links
HemoShear Announces Advancement of Predictive Drug Safety Systems
Date:7/18/2013

CHARLOTTESVILLE, Va., July 18, 2013 /PRNewswire/ -- HemoShear, LLC, a leading developer of human-relevant systems for drug development and discovery, today announced an important milestone in the development of systems that predict safety of new drugs and chemicals. Published in the American Journal of Physiology – Cell Physiology, the manuscript entitled "Hemodynamic flow improves rat hepatocyte morphology, function and metabolic activity in vitro" reports HemoShear's success in applying the core principles of its technology to replicate liver biology on the laboratory bench.  Development of non-human species systems is an important step towards systems that use human cells to predict drug and chemical effects in humans. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

HemoShear's work is valuable to the pharmaceutical industry because drug-induced liver injury, which is often not detected in pre-clinical animal and cell-culture studies, remains the most frequent cause of drug-induced toxicity and toxicity-related failures in clinical trials.  By accurately replicating organ and disease biology in the laboratory, HemoShear's human-relevant systems will reduce the risk of costly failures in clinical trials and accelerate development of safe and effective drugs in humans. 

Ajit Dash, M.D., Ph.D., HemoShear's Senior Director of Liver Systems, explains the significance of HemoShear's achievement.  "In contrast to traditional methods that do not provide critical physiological cues to restore human cell biology, HemoShear's principles of combining primary cells and fluid circulation patterns restore the most important biological functions of hepatocytes, which are necessary for prediction of drug metabolism and safety," said Dr. Dash.

"Our work on the rat system has enabled significant progress in developing a human liver surrogate system, which is currently being validated with known drugs.  HemoShear has already validated a physiologically accurate vascular system and vascular disease conditions.  By gaining access to our liver and vascular systems and diseases, our pharmaceutical partners can save millions of dollars by avoiding drugs that are doomed to fail, while redirecting precious resources to drug candidates that are more likely to succeed in humans," said Brian Wamhoff, Ph.D., HemoShear's co-founder and Vice President of R&D.

HemoShear's publication may be found at the following address:   
http://www.ncbi.nlm.nih.gov/pubmed/23485712

Dash A, Simmers MB, Deering TG, Berry DJ, Feaver RE, Hastings NE, Pruett TL, Lecluyse EL, Blackman BR, Wamhoff BR. Hemodynamic Flow Improves Rat Hepatocyte Morphology, Function and Metabolic Activity in vitro. Am J Physiol Cell Physiol. 2013 Mar 13 [Epub ahead of print]

About HemoShear, LLC

By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

For information about HemoShear, please visit www.hemoshear.com.


'/>"/>
SOURCE HemoShear, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
2. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
3. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
4. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
5. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
6. Cardium Announces Reverse Stock Split
7. STAAR Surgical Announces Second Quarter 2013 Results Release Date And Conference Call And Webcast
8. RXi Pharmaceuticals Announces CEO Interview
9. Bureau Veritas Announces Sargam Laboratory Private Limited Name Change
10. Comco Plastics Inc. Announces Its Expansion & Separation From The NYTEF Group.
11. Hill-Rom Announces Preliminary Fiscal 2013 Third Quarter Results and Search for New CFO; Adjusted Earnings Per Share Expected to be in Line with Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):